ŞENDUR, M. A. N. Et Al. 2014. Comparison of the efficacy of 9 weeks versus 52 weeks of adjuvant trastuzumab treatment in HER 2 positive early stage breast cancer with axillary lymph node metastases. 39th Esmo Congress .

ŞENDUR, M. A. N., ÖZDEMİR, N., Ozatlı, T., YAZICI, O., Ekinci, A. S., Yazılıtas, D., ... AKSOY, S.(2014). Comparison of the efficacy of 9 weeks versus 52 weeks of adjuvant trastuzumab treatment in HER 2 positive early stage breast cancer with axillary lymph node metastases . 39th Esmo Congress

ŞENDUR, MEHMET Et Al. "Comparison of the efficacy of 9 weeks versus 52 weeks of adjuvant trastuzumab treatment in HER 2 positive early stage breast cancer with axillary lymph node metastases," 39th Esmo Congress, 2014

ŞENDUR, MEHMET A. Et Al. "Comparison of the efficacy of 9 weeks versus 52 weeks of adjuvant trastuzumab treatment in HER 2 positive early stage breast cancer with axillary lymph node metastases." 39th Esmo Congress , 2014

ŞENDUR, M. A. N. Et Al. (2014) . "Comparison of the efficacy of 9 weeks versus 52 weeks of adjuvant trastuzumab treatment in HER 2 positive early stage breast cancer with axillary lymph node metastases." 39th Esmo Congress .

@conferencepaper{conferencepaper, author={MEHMET ALİ NAHİT ŞENDUR Et Al. }, title={Comparison of the efficacy of 9 weeks versus 52 weeks of adjuvant trastuzumab treatment in HER 2 positive early stage breast cancer with axillary lymph node metastases}, congress name={39th Esmo Congress}, city={}, country={}, year={2014}}